Encephalitis, Japanese B Completed Phase 3 Trials for Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)

Also known as: Japanese Encephalitis / Encephalitis Japanese B / Encephalitis, Japanese / Japanese B encephalitis / Japanese B viral encephalitis

IndicationStatusPhase
DBCOND0033957 (Encephalitis, Japanese B)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00249769Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccinePrevention
NCT00314132Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.Prevention
NCT00594958Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51Prevention
NCT00595790Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51Prevention
NCT00595309Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51Prevention
NCT00596271Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440Prevention
NCT00595270Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51Prevention
NCT00605085Safety and Tolerability of the Japanese Encephalitis Vaccine IC51Prevention
NCT00604708Immunogenicity Study of the Japanese Encephalitis Vaccine IC51Prevention
NCT00735644Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the PhilippinesPrevention
NCT00776230Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingPrevention
NCT01246479Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyOther
NCT01296360Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryPrevention
NCT01386827Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisPrevention
NCT01466387A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsPrevention